Emergent BioSolutions (EBS)

Emergent BioSolutions (EBS) is a specialty pharmaceutical company that develops, manufactures, and commercializes a variety of specialized products for use in biodefense and commercial markets in the US and internationally. EBS’s Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent for the treatment of suspected or documented exposure to botulinum neurotoxin; Anthrax Immune Globulin (AIG) Intravenous to treat toxemia associated with inhalational anthrax; Vaccinia Immune Globulin Intravenous for addressing adverse events from smallpox vaccination; and RSDL (reactive skin decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. The Biosciences segment markets WinRho to treat autoimmune platelet disorder and hemolytic diseases in newborns; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; Varizig for post-exposure prophylaxis of chickenpox; Episil to treat pain associated with oral mucositis; and Ixinity, a therapeutic to prevent bleeding episodes in people with hemophilia